<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80557">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841047</url>
  </required_header>
  <id_info>
    <org_study_id>IB2008-42</org_study_id>
    <nct_id>NCT01841047</nct_id>
  </id_info>
  <brief_title>Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma</brief_title>
  <acronym>TOMOREP</acronym>
  <official_title>Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retro peritoneal liposarcomas are rare (less than 15% of sarcomas) whose prognosis is
      locoregional.

      In the treatment of retroperitoneal liposarcomas main prognostic factor is the quality of
      the surgical resection. The effect of radiotherapy combined with surgery is uncertain and
      until now limited perhaps because of limited prescribed doses (of the order of 45Gy to 50Gy)
      due to high risk of organ toxicity nearby.

      The helical tomotherapy is an innovative equipment radiotherapy to make conformational
      radiotherapy modulation intensity and is particularly suitable for irradiations precision
      (imaging mode associated with daily scanner) in large complex volumes. Increasing doses
      (increase of the prescribed dose to 54 Gy, thus potentially curative), the helical
      tomotherapy should allow to improve the efficacy of radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retro peritoneal liposarcomas are rare (less than 15% of sarcomas) whose prognosis is
      locoregional. In the treatment of retroperitoneal liposarcomas main prognostic factor is the
      quality of the surgical resection. The effect of radiotherapy combined with surgery is
      uncertain and until now limited perhaps because of limited prescribed doses (of the order of
      45Gy to 50Gy) due to high risk of organ toxicity nearby.

      Two elements can overcome these difficulties:

        -  Preoperative radiotherapy made ​​rather than Postoperatively, the tumor in place back
           the gastrointestinal tract and reducing toxicity,

        -  The contribution of conformal radiotherapy techniques with intensity modulation (IMRT).
           The helical tomotherapy is an innovative equipment radiotherapy to make conformational
           radiotherapy modulation intensity and is particularly suitable for irradiations
           precision (imaging mode associated with daily scanner) in large complex volumes.
           Increasing doses (increase of the prescribed dose to 54 Gy, thus potentially curative),
           the helical tomotherapy should allow to improve the efficacy of radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>disease-free survival Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable.</measure>
    <time_frame>08/2013 (3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable. The effectiveness will be evaluated in terms of disease-free survival Local 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the toxicity of the combination radio-surgical</measure>
    <time_frame>08/2013 (1, 3, 5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the toxicity of the combination radio-surgical
Assessment of local recurrence-free survival at 1 year and 5 years
Evaluation of overall survival at 1, 3 and 5 years,
Description of the technical feasibility of the association radiosurgery, in terms of compliance with the prescribed dose of dose constraints modulated conformal radiotherapy intensity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation of the combination of radiotherapy with tomotherapy coil (54 Gy) followed by surgery in liposarcomas retroperitoneal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liposarcoma histologically proven, in case of non-biopsy contributive: diagnosis
             radiologically validated meeting multidisciplinary consultation (RCP)

          2. Protocol TOMOREP technically feasible,

          3. Patients over 18 years

          4. Considered a priori tumor operable even with excision multi-visceral

          5. Absence of morbidity against-indicating surgery necessary

          6. Original form (as well as tumors made ​​after first incomplete excision) and form in
             first relapse.

          7. Life expectancy greater than 6 months

          8. Patient signed informed consent,

          9. Patient affiliated to a social security scheme.

        Exclusion Criteria:

          1. Metastasis associated

          2. Extension intraperitoneal associated mesenteric extension

          3. bilaterally

          4. Against disease-indicating the need for surgery (ASA 3 and 4).

          5. Cons-indication for radiotherapy (such as prior radiotherapy the volume to be
             treated).

          6. Patient included in another clinical study

          7. Unable to undergo medical monitoring test for geographical, social or psychological,

          8. Private patient freedom and major subject of a measure of legal protection or unable
             to consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KANTOR Guy, PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KANTOR Guy, PU-PH</last_name>
    <email>g.kantor@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MATHOULIN PELISSIER Simone, PU-PH</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NOEL Georges, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>NOEL Georges, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KANTOR Guy, PU-PH</last_name>
      <email>g.kantor@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>KANTOR Guy, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAPETITE Claire, MD</last_name>
    </contact>
    <investigator>
      <last_name>ALAPETITE Claire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DELANNES Martine, MD</last_name>
    </contact>
    <investigator>
      <last_name>DELANNES Martine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <state>Pays de la Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAHE Marc André, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>MAHE Marc André, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.bergonie.org/fr/essais-clinique.html</url>
    <description>Site internet du promoteur, l'Institut Bergonié</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retroperitoneal liposarcoma operable</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Retroperitoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
